Pakistan’s Drug Regulatory Authority (DRAP) has warned the Ministry of Health against vaccinating China’s Sinopharm COVID-19 vaccine to people with weakened immune systems.
DRAP has highlighted that any serious adverse reaction will trigger public disinformation instances that could challenge the nationwide immunization campaign.
In this regard, DRAP instructed the Ministry of Health to develop comprehensive Adverse Events Following Immunization (AEFI) strategy and submit its data to the National Pharmacovigilance Center (NPC).
DRAP will use this data to quarterly review the Emergency Use Authorization (EUA) status of the Sinopharm coronavirus vaccine.
It was previously reported that the Sinopharm vaccine is not suitable for people between the ages of 18 and 60. Also not recommended for pregnant and lactating women.
Patients with a history of serious chronic diseases or disorders, as well as those who are allergic to any component (active, excipient) of the vaccine, are also not recommended to inject Sinopharm vaccine.
It is expected that those at risk of the Sinopharm COVID-19 vaccine will be vaccinated with Oxford-AstraZeneca vaccine which has proved to be suitable for all ages during trials.
Pakistan has received 17 million doses of the AstraZeneca coronavirus vaccine through GAVI, of which 7 million will arrive in the country later this month.
Latest posts by News Desk (see all)
- FBR asked to enhance efforts for Broadening Tax Net - May 27, 2023
- National Savings Rate for June-2023 - May 27, 2023
- Islamabad to get a new “Luxury Resort” - May 27, 2023